NXI Therapeutics is a spin-off from the Biozentrum at the University of Basel focused on developing disruptive immunotherapies by modulating coronin 1 in immune cells. In preclinical models, coronin 1 depletion enables long-term acceptance of genetically unrelated organ transplants, prevents graft-versus-host disease, and protects against several autoimmune disorders while preserving a normal lifespan without infections or cancer. The company is targeting clinical applications in T cell–mediated autoimmune conditions and transplantation medicine. NXI has received support from Venture Kick, BaseLaunch, Innobooster, an InnoBooster grant from the Gebert Rüf Foundation and a Propelling grant from the University of Basel. It has extended its pre-seed financing to CHF 3.5 million and is currently raising a larger Seed financing. Lead investor JFG Life Sciences Foundation participated in the extension and Kickfund, BaseLaunch and Venture Kick are named participants; Patrick Burgermeister of JFG will join NXI’s board.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2024